110 related articles for article (PubMed ID: 16319527)
1. Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis.
Messersmith W; Oppenheimer D; Peralba J; Sebastiani V; Amador M; Jimeno A; Embuscado E; Hidalgo M; Iacobuzio-Donahue C
Cancer Biol Ther; 2005 Dec; 4(12):1381-6. PubMed ID: 16319527
[TBL] [Abstract][Full Text] [Related]
2. Hitting the target: measuring EGFR response to tyrosine kinase inhibitors.
Nyati MK; Lawrence TS
Cancer Biol Ther; 2005 Dec; 4(12):1387-8. PubMed ID: 16418570
[No Abstract] [Full Text] [Related]
3. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa.
Bhargava R; Chen B; Klimstra DS; Saltz LB; Hedvat C; Tang LH; Gerald W; Teruya-Feldstein J; Paty PB; Qin J; Shia J
Cancer; 2006 Apr; 106(8):1857-62. PubMed ID: 16532444
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia.
Isidro RA; Cruz ML; Isidro AA; Baez A; Arroyo A; González-Marqués WA; González-Keelan C; Torres EA; Appleyard CB
World J Gastroenterol; 2015 Feb; 21(6):1749-58. PubMed ID: 25684939
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor levels are lower in carcinomatous than in normal colorectal tissue.
Koenders PG; Peters WH; Wobbes T; Beex LV; Nagengast FM; Benraad TJ
Br J Cancer; 1992 Feb; 65(2):189-92. PubMed ID: 1739615
[TBL] [Abstract][Full Text] [Related]
6. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
Gori S; Sidoni A; Colozza M; Ferri I; Mameli MG; Fenocchio D; Stocchi L; Foglietta J; Ludovini V; Minenza E; De Angelis V; Crinò L
Ann Oncol; 2009 Apr; 20(4):648-54. PubMed ID: 19188134
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2.
Maurer CA; Friess H; Kretschmann B; Zimmermann A; Stauffer A; Baer HU; Korc M; Büchler MW
Hum Pathol; 1998 Aug; 29(8):771-7. PubMed ID: 9712416
[TBL] [Abstract][Full Text] [Related]
8. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
Słodkowska J; Filas V; Buszkiewicz E; Trzeciak P; Wojciechowski M; Koktysz R; Staniszewski W; Breborowicz J; Rojo MG
Folia Histochem Cytobiol; 2010 Jan; 48(1):19-25. PubMed ID: 20529811
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
Tan AR; Yang X; Hewitt SM; Berman A; Lepper ER; Sparreboom A; Parr AL; Figg WD; Chow C; Steinberg SM; Bacharach SL; Whatley M; Carrasquillo JA; Brahim JS; Ettenberg SA; Lipkowitz S; Swain SM
J Clin Oncol; 2004 Aug; 22(15):3080-90. PubMed ID: 15284258
[TBL] [Abstract][Full Text] [Related]
10. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
Efferth T
Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
[TBL] [Abstract][Full Text] [Related]
11. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.
Cunningham MP; Thomas H; Fan Z; Modjtahedi H
Cancer Res; 2006 Aug; 66(15):7708-15. PubMed ID: 16885373
[TBL] [Abstract][Full Text] [Related]
12. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
13. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity?
Saltz L
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S98-100. PubMed ID: 16336755
[TBL] [Abstract][Full Text] [Related]
15. Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers.
Harlé A; Salleron J; Perkins G; Pilati C; Blons H; Laurent-Puig P; Merlin JL
Br J Cancer; 2015 Aug; 113(4):680-5. PubMed ID: 26171935
[TBL] [Abstract][Full Text] [Related]
16. Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases.
Karameris A; Kanavaros P; Aninos D; Gorgoulis V; Mikou G; Rokas T; Niotis M; Kalogeropoulos N
Pathol Res Pract; 1993 Mar; 189(2):133-7. PubMed ID: 8321742
[TBL] [Abstract][Full Text] [Related]
17. Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis.
Pfeiffer P; Nexø E; Bentzen SM; Clausen PP; Andersen K; Rose C
Br J Cancer; 1998 Jul; 78(1):96-9. PubMed ID: 9662257
[TBL] [Abstract][Full Text] [Related]
18. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.
Personeni N; Hendlisz A; Gallez J; Galdon MG; Larsimont D; Van Laethem JL; Nagy N; Barette M; Paesmans M; Cardoso F; Bleiberg H
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S59-62. PubMed ID: 16399434
[TBL] [Abstract][Full Text] [Related]
19. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
20. The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
Shao G; Wang R; Sun A; Wei J; Peng K; Dai Q; Yang W; Lin Q
Mol Cancer; 2018 Feb; 17(1):24. PubMed ID: 29455656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
